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Purpose/Objective: In contrast to patients with early stage 
NSCLC, clear recommendations are still missing for SBRT for 
lung metastases regarding patient selection, planning, 
delivery, dose and quality assurance. This report of the 
German working group stereotactic radiotherapy pools SBRT 
patient data of German centers and aims to describe local 
control, overall survival, prognostic factors and dose 
recommendations in respect to the different primary 
subgroups. 
Materials and Methods: All radiotherapy departments in 
Germany were contacted and invited to participate in this 
study. 700 patients with 963 lung metastases treated with 
SBRT were included in this database. The analyzed subgroups 
were NSCLC (25.7%), colorectal cancer (22.6%), renal cell 
cancer (6.7%), breast cancer (6.2%) and sarcoma. 30% of the 
lesions were treated as single fraction radiosurgery, 36% in a 
three fraction approach, 34% lesions with different 
fractionation.  
Results: Median follow-up time was 26.4 months. For the 
entire patient cohort, an excellent local control rate after 1 
year of 90.8% and after 2 years of 81.4% was detected. In 
detail, the best 1-year- and 2-year-local control rate was 
achieved for breast cancer (97.5% vs. 97.5%), followed by 
renal cell carcinoma (96.2% vs. 93.3%), NSCLC (94.7% vs. 
76.2%), colorectal cancer (88.3% vs. 81.2%) and sarcoma 
(68.7% vs. 45.8%). For the entire patient cohort, local control 
was significantly influenced by primary tumor histology, 
Karnofsky performance scale, localization (central vs. 
peripheral), time of metastases detection (synchronous vs. 
metachronous) and maximum tumor diameter. 2-year overall 
survival rates were 64.5% for breast cancer, 66.1% for 
colorectal cancer, 62.7% for renal cell carcinoma, 54.7% for 
NSCLC and 39.1% for sarcoma. Additionally, conducting 
biological modeling we tried to propose primary specific dose 
recommendations needed for 90%-2-year-local control for the 
different tumor entities (e.g. BED= 97.5 Gy for NSCLC vs. BED 
= 108.8 Gy for colorectal cancer). 
Conclusions: SBRT for lung metastases from different 
primary tumors was effective and safe despite considerable 
interinstitutional variability in SBRT practice throughout 
Germany. Prognostic factors and doses for 90%-local control 
are truly dependent on the different primary tumors. Future 
prospective studies are of highly interest to evaluate dose 
recommendations and prognostic factors. 
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Purpose/Objective: Many head and neck cancer survivors 
experience reduced quality of life due to radiotherapy-
related dysphagia and swallowing exercises have been 
suggested as an option for treatment hereof. The aim of this 
meta-analysis was to evaluate the impact of prophylactic 
swallowing exercises on swallowing-related outcomes in head 
and neck patients treated with curative radiotherapy.  
Materials and Methods: Pubmed was searched for 
publications up to Oct 30th 2014 on subject headings for the 
following concepts: swallowing exercises, dysphagia 
rehabilitation, radiotherapy and head and neck cancer; all 
reference lists in the selected journal articles were 
additionally screened for potentially relevant articles. 
Included papers contained information on objective 
endpoints (N=4), observer-rated endpoints (N=8), patient-
rated endpoints (N=5), clinical endpoints (N=10) or a 
combination of these. A meta-analysis of PEG tube incidence 
was performed using 'Comprehensive Meta-analysis'; a p value 
≤ 0.05 was considered significant. 
Results: A total of 12 papers were included. In general, most 
of the studies reported some positive results of swallowing 
therapy but a comparison was complicated by the broad 
range of interventions, evaluation times and endpoints used 
and the benefit was not consistent and not related to specific 
measures.  
Incidence of PEG tube was the endpoint most often reported 
(N=9) and the only endpoint suited for meta-analysis. In the 
current setting, four studies reported a benefit from 
prophylactic exercises and five studies reported no difference 
on PEG tube incidence. A meta-analysis of these studies 
regardless of evaluation time and design (Figure 1) showed an 
overall benefit of prophylactic exercises with an odds ratio of 
0.30 (95% CI: 0.21-0.44). This benefit remained if only 
randomized controlled trials (RCTs) or studies examining 
incidence of tube feeding ≥ 6 months post-treatment was 
used. 
 
 
Conclusions:  
The meta-analysis showed a positive impact of prophylactic 
swallowing exercises on PEG tube incidence; it was not 
possible to examine other endpoints in this meta-analysis due 
to heterogeneous use of evaluation methods and scales. 
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Purpose/Objective: To determine the maximum tolerated 
dose (MTD) of an hypofractionated accelerated IMRT 
treatment with the simultaneous integrated boost (SIB) 
technique in patients with < 5 brain metastases.  
Materials and Methods: Patients with < 5 brain metastases 
and no extra-cranial disease were enrolled in a phase I study. 
IMRT was delivered over 2 weeks in 10 fractions to the two 
planning target volumes (PTVs) defined by adding 5-mm 
margin to the respective clinical target volumes (CTVs). The 
CTV1 was defined as each single lesion (GTV) on the basis of 
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the contrast-enhanced MRI imaging. CTV2 encompassed the 
whole brain. Only the PTV1 dose was escalated (planned dose 
escalation: 35 Gy, 40 Gy, 45 Gy, 50 Gy) while the PTV2 dose 
remained the same (30 Gy/3 Gy/fractions). Dose-limiting 
toxicities (DLTs) were defined as any treatment-related non-
hematological adverse effects rated as grade ≥ 3, or any 
hematological toxicity rated as ≥ 4 by CTCAE scale, v. 4.0. 
MTD was exceeded if > 2 of 6 patients in a cohort 
experienced dose-limiting toxicity (DLT).  
Results: 27 consecutive patients (pts) were treated (PTV1 
dose: 35 Gy, 8 pts; 40 Gy, 6 pts; 45 Gy, 6 pts; 50 Gy, 7 pts). 
The number of treated brain lesions was: 1 (17 pts), 2 (4 pts), 
3 (5 pts) and 4 (1 pt). Three pts experienced a DLT: 1 pt (2nd 
dose level) developed a grade 3 skin toxicity, 1 pt had a 
grade 3 neurological toxicity (4th dose level) and 1 pt had a 
brain hemorrhage (4th dose level). Nineteen pts experienced 
cutaneous (17 pts) and/or neurological (10 pts) grade 1-2 
acute toxicity. The response to treatment was evaluable in 
16 pts: 1 pt (6.2%) disease progression, 2 pts (12.5%) stable 
disease, 10 pts (62.5%) partial response and 3 pts (18.8%) 
complete response. Median and 1-year overall survival were 
13 months and 51.9%, respectively. Late toxicity was not 
recorded. 
Conclusions: This is the first prospective trial demonstrating 
that a radiation dose of 50 Gy in 10 fractions can be 
delivered by using a SIB IMRT technique without unacceptable 
toxicity in patients with < 5 brain metastases. A phase II trial 
(ISIDE-BM-2) is in progress to evaluate the response and the 
time to progression. 
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Purpose/Objective: Stereotactic ablative body radiotherapy 
(SABR) is the standard treatment modality for a limited 
number of brain metastases (BM). Several models for survival 
prediction have been published, such as the commonly used 
Recursive Partitioning Analysis (RPA), Golden Grading System 
(GGS), and the Disease Specific Graded Partitioning Analysis 
(DS-GPA). All published models have limitations for 
prediction of survival after SABR for BM: e.g. small proportion 
of patients in the favorable prognostic group, a low 
sensitivity for the identification of patients with long term 
survival, and some models are complex to use (e.g. DS-GPA). 
In this study, a new prognostic model is developed with the 
aim of overcoming above mentioned limitations. 
Materials and Methods: Based on published models and 
clinical practice a new prognostic model was developed. Its 
clinical utility was tested for prediction of early death (<3 
months) and long term survival (>12 months) in 297 patients 
with 1 up to 4 newly diagnosed BM treated with Linac-based 
SABR at our department between July 2004 and July 2014. 
Prescribed dose at the edge of the PTV was in the range of 15 
up to 24Gy in 1 or 3 fractions.  
Results: In the published models the two most important 
prognostic factors were: WHO performance status and 
presence of extracranial metastases. Poor performance 
status only was identified as the poor prognostic group 
according to Dutch guidelines. Remaining patient cohort was 
divided based on the presence of extracranial metastases. 
The developed model is a simplified version of the commonly 
used RPA, and was named Simplified Recursive Partitioning 
Analysis (SRPA). 
- SRPA class I: WHO performance status 0/1 & no extracranial 
metastases 
- SRPA class II: WHO performance status 0/1 & extracranial 
metastases 
- SRPA class III: WHO performance status of 2 or more 
Median age was 63 years and the majority of patients had 
non-small cell lung cancer (64%). The median survival after 
SABR was 9 months, with 3 months-, 1 year-, and 5 years 
survival of respectively 81%, 36%, and 9%. The patient 
distribution was most balanced in the SRPA with 48% of 
patients in the favorable prognostic class (vs 20%-29% in the 
other models, Table 1). Sensitivity for prediction of long-
term survival was highest using the SRPA (56% vs 16-46% in 
other classes). The specificity of predicting 3-months death 
in the poor prognostic class was high in all scores (range 86% 
up to 98%). The SRPA was valid in an external SABR for 1-3 BM 
patients data set. 
 
 
 
 
Conclusions: The SRPA had the highest clinical utility for 
survival prediction after SABR for BM compared to the RPA, 
DS-GPA, and GGS. The SRPA is very simple in use, assembles 
to clinical practice, has a balanced patient distribution 
between the favorable and intermediate group, the highest 
sensitivity for prediction of long term survival, was specific 
for prediction of early death, and was validated in an 
external population. Further research will focus on further 
validation in other BM populations and exploration of the 
predictive value of advanced techniques such as radiomics, 
biomarkers, and statistical modeling. 
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